Drug Trial Radar · NCT06886464
Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
698
Planned (sponsor's estimate)
Start
Jul 16, 2025
Primary completion
Dec 31, 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- Matthew JamesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alberta Health services; University of Alberta
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to repurpose cilastatin for preventing acute kidney injury (AKI) in hospitalized patients receiving nephrotoxic medications. The trial will evaluate the efficacy of the re-purposed drug. The main questions it aims to answer are: \- whether cilastatin will prevent nephrotoxic AKI in hospitalized patients. Researchers will compare the drug cilastatin to a placebo (a look-alike substance that contains no drug) to see if drug cilastatin works to prevent AKI in hospitalized patients receiving nephrotoxic medications. Participants will: * Receive drug Cilastatin or a placebo intravenously every 6 hours for up to 24 hours after last exposure to nephrotoxic medication * Have blood test for kidney function every day they are on treatment. * Have a follow-up blood test at 90 days after randomization * Have a telephone survey at 90 days after randomization
Conditions
- Acute Kidney Injury
Interventions
Cilastatin SodiumDrug
Intravenous cilastatin reconstituted in normal saline solution
Placebo-SalineDrug
Identical looking normal saline solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants developing AKITime frame: 7 days after administration of a nephrotoxic medication
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Calgary
Calgary, Alberta, Canada · Recruiting
University of Alberta
Edmonton, Alberta, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.